Kalliala Ilkka, Dyba Tadeusz, Nieminen Pekka, Hakulinen Timo, Anttila Ahti
Mass Screening Registry, Finnish Cancer Registry, Pieni Roobertinkatu, Helsinki, Finland.
Int J Cancer. 2010 Jan 1;126(1):224-31. doi: 10.1002/ijc.24713.
After treatment of the cervical intraepithelial neoplasia (CIN) cervical cancer incidence remains elevated at least for 20 years. Whether the overall or cervical cancer mortality after treatment of CIN is elevated is unknown. The aim of this study was to determine the long-term survival and cause-specific mortality among women treated for CIN. The study population consisted of 7,104 women treated for CIN between 1974 and 2001 and 35,437 individually matched controls. The follow-up of mortality was based on nationwide registries and closed at death, emigration or December 31, 2005. The possible differences in mortality were assessed using Cox proportional hazard model. With follow-up time of approximately 630,000 woman-years, overall 2,781 deaths were observed, 530 among women treated for CIN and 2,251 among reference population (HR 1.1, 95% CI 1.0-1.3). Mortality from any cancer (HR 1.4, 95% CI 1.2-1.7), lung cancer (HR 2.7, 95% CI 1.8-4.1) and HPV-related anogenital cancer (HR 3.1, 95% CI 1.1-8.6) was higher among CIN patients, but mortality from cervical cancer was not (HR 1.0, 95% CI 0.3-4.0). Elevated cervical cancer incidence after treatment of CIN, documented earlier, did not predict elevation in cervical cancer mortality. This suggests high effectiveness of CIN management. Most of the excess mortality observed among CIN patients was due to increased risk of other cancers. These long-term mortality patterns should be considered when planning and evaluating the management of CIN lesions and related cervical or other cancer prevention activity.
在治疗宫颈上皮内瘤变(CIN)后,宫颈癌发病率至少在20年内仍保持升高。CIN治疗后的总体死亡率或宫颈癌死亡率是否升高尚不清楚。本研究的目的是确定接受CIN治疗的女性的长期生存率和特定病因死亡率。研究人群包括1974年至2001年间接受CIN治疗的7104名女性和35437名个体匹配对照。死亡率随访基于全国登记系统,随访在死亡、移民或2005年12月31日结束。使用Cox比例风险模型评估死亡率的可能差异。随访时间约为630000人年,共观察到2781例死亡,其中接受CIN治疗的女性中有530例死亡,参照人群中有2251例死亡(风险比1.1,95%置信区间1.0 - 1.3)。CIN患者中任何癌症(风险比1.4,95%置信区间1.2 - 1.7)、肺癌(风险比2.7,95%置信区间1.8 - 4.1)和人乳头瘤病毒(HPV)相关的肛门生殖器癌(风险比3.1,95%置信区间1.1 - 8.6)的死亡率较高,但宫颈癌死亡率并非如此(风险比1.0,95%置信区间0.3 - 4.0)。先前记录的CIN治疗后宫颈癌发病率升高并未预示宫颈癌死亡率升高。这表明CIN管理具有高效性。CIN患者中观察到的大部分额外死亡率归因于其他癌症风险增加。在规划和评估CIN病变管理以及相关宫颈癌或其他癌症预防活动时,应考虑这些长期死亡率模式。